Pelosi also said it's "irrelevant" whether approving the USMCA trade deal would give President Donald Trump a victory ahead of the 2020 election.Politicsread more
Brent crude oil jumped the most in history in the previous session after attacks on Saudi's oil industry disrupted the kingdom's production.Marketsread more
General Motors stands to lose hundreds of millions of dollars in lost production as a United Auto Workers union strike against the automaker enters its second day, but Wall...Autosread more
Damage to the top OPEC producer's oil facilities ignited fears of supply disruption around the world and has sent crude prices soaring.Energyread more
The second-largest investor in Kraft Heinz Company discloses that it has again trimmed its stake in the food company.Marketsread more
"That leads the developed world to say to China: 'We've got to rebalance this. It's working for you. It's not working for us,'" says the billionaire Blackstone co-founder.Economyread more
Microsoft founder Bill Gates takes an aggressive approach to investing, despite being the second richest person in the world.Wealthread more
These are the stocks posting the largest moves in midday trading.Market Insiderread more
Viacom chief executive officer Bob Bakish is not worried about competition in the streaming space, on the heels of its merger with CBS.The Faber Reportread more
Consumers could pay an average 15 to 20 cents more per gallon for unleaded gas by the end of the month following the attack on Saudi oil installations.Market Insiderread more
Bob Bakish, the head of a newly combined CBS and Viacom, said he was "disappointed" by both stocks' reaction to the recent deal.The Faber Reportread more
Former FDA Commissioner Scott Gotlieb told CNBC on Tuesday that "Medicare for All" — favored by many of the candidates seeking the 2020 Democratic presidential nomination — would eventually lead to a decline in health-care services in America.
"I don't think it is that feasible, quite frankly," said Gottlieb, who stepped down in April as the leader of the Food and Drug Administration under President Donald Trump. Medicare for All "would crowd out competition in private insurance and crowd out the kind of competition that puts downward pressure" on prices of drugs and medical services, Gottlieb said.
Trump, who appointed Gottlieb, has also criticized a Medicare for All approach. The president, a proponent of decreasing costs in health care, has tried to repeal and replace Obamacare.
In a "Squawk Box" interview, Gottlieb said, "Most of the changes in the practice of medicine have resulted from private coverage, and Medicare has been behind," said Gottleib, who early in his career completed a residency in internal medicine at the Mount Sinai Medical Center in New York. He added that Medicare has been "slow to embrace changes to the practice of medicine."
Referring to CAR-T cancer treatments, a gene therapy approach that has been FDA approved for about two years, he said, "Medicare hasn't figured out how to pay on the delivery of this medicine."
"When hospitals deliver this they're losing money on it," he claimed, saying they turn to clinical trials where the hospital will be reimbursed for the medication.
Meanwhile, Sen. Elizabeth Warren, also a Democratic presidential candidate, called on Gottlieb to resign from Pfizer's board.
"This kind of revolving door influence-peddling smacks of corruption, and makes the American people rightly cynical and distrustful about whether high-level Trump administration officials are working for them, or for their future corporate employers," Warren said in a letter on July 1, to Gottlieb.
— CNBC's Angelica Lavito contributed to this report.